Prevent Blindness, the nation's leading patient advocacy organization dedicated to preventing blindness and preserving sight, ...

Patients with noninfectious intermediate, posterior, or panuveitis requiring immunosuppressive therapy are less likely to ...

YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications - adolescent hidradenitis suppurativa (HS) and ...

ORLANDO -- Adalimumab (Humira) was more effective than conventional immunosuppressive drugs at lowering or eliminating the ...

YUFLYMA® (adalimumab-aaty), and its unbranded version, are now approved for two additional pediatric indications - adolescent hidradenitis suppurativa (HS) and pediatric uveitis (UV), in the ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ...

Intermediate filaments (IFs) are assembled from fibrous proteins that exhibit a central α-helical rod domain with a conserved substructure. This rod domain facilitates the formation of dimeric ...

Vanguard Interm-Term Treasury Fund earns a High Process Pillar rating. The main driver of the rating is its parent firm's excellent long-term risk-adjusted performance, as shown by the firm's average ...

2-Year U.S. Treasury Note Continuous Contract $104.434 0.012 0.01% 5-Year U.S. Treasury Note Continuous Contract $109.773 0.023 0.02% 10-Year U.S. Treasury Note Continuous Contract $113.453 0.047 0.04 ...